Sk Biopharmaceuticals Co Ltd (326030)

Seoul
Currency in KRW
127,900
+900(+0.71%)
Closed
326030 Scorecard
Full Analysis
Net income is expected to grow this year
Unusual trading volume
Fair Value
Day's Range
124,200127,900
52 wk Range
72,600130,000
Key Statistics
Edit
Bid/Ask
127,800.00 / 127,900.00
Prev. Close
127,000
Open
125,000
Day's Range
124,200-127,900
52 wk Range
72,600-130,000
Volume
613.18K
Average Volume (3m)
299.34K
1-Year Change
49.77%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
326030 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
129,438
Upside
+1.20%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Sk Biopharmaceuticals Co Ltd Company Profile

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments; and research collaboration agreement with ProEn Therapeutics for accelerating expansion of oncology research and pipeline for radiopharmaceuticals. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.

Employees
241

Compare 326030 to Peers and Sector

Metrics to compare
326030
Peers
Sector
Relationship
P/E Ratio
174.6x−1.7x−0.6x
PEG Ratio
1.030.060.00
Price/Book
29.6x1.9x2.6x
Price / LTM Sales
19.6x2.2x3.1x
Upside (Analyst Target)
9.5%93.1%47.1%
Fair Value Upside
Unlock11.0%8.1%Unlock

Analyst Ratings

12 Buy
3 Hold
1 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 129,438
(+1.20% Upside)

Earnings

Latest Release
Feb 06, 2025
EPS / Forecast
197.19 / 67.49
Revenue / Forecast
163.00B / 150.45B
EPS Revisions
Last 90 days

People Also Watch

136,900
000100
-0.36%
15,150
024110
-0.13%
391,000
267260
-1.76%
45,350
030200
-1.52%
311,000
329180
+2.64%

FAQ

What Is the Sk Biopharma (326030) Stock Price Today?

The Sk Biopharma stock price today is 127,900.00

What Stock Exchange Does Sk Biopharma Trade On?

Sk Biopharma is listed and trades on the Seoul stock exchange.

What Is the Stock Symbol for Sk Biopharma?

The stock symbol for Sk Biopharma is "326030."

What Is the Sk Biopharma Market Cap?

As of today, Sk Biopharma market cap is 10.02T.

What is Sk Biopharma Earnings Per Share?

The Sk Biopharma EPS is 732.73.

What Is the Next Sk Biopharma Earnings Date?

Sk Biopharma will release its next earnings report on 07 May 2025.

From a Technical Analysis Perspective, Is 326030 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.